163 related articles for article (PubMed ID: 8740095)
21. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.
Hughes GS; Heald DL; Barker KB; Patel RK; Spillers CR; Watts KC; Batts DH; Euler AR
Clin Pharmacol Ther; 1989 Dec; 46(6):674-85. PubMed ID: 2557183
[TBL] [Abstract][Full Text] [Related]
22. A review of the pharmacokinetics of cefpodoxime proxetil.
Borin MT
Drugs; 1991; 42 Suppl 3():13-21. PubMed ID: 1726203
[TBL] [Abstract][Full Text] [Related]
23. Cefpodoxime pharmacokinetics in children: effect of food.
Kearns GL; Abdel-Rahman SM; Jacobs RF; Wells TG; Borin MT
Pediatr Infect Dis J; 1998 Sep; 17(9):799-804. PubMed ID: 9779765
[TBL] [Abstract][Full Text] [Related]
24. Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil.
Couraud L; Andrews JM; Lecoeur H; Sultan E; Lenfant B
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():35-40. PubMed ID: 2292528
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.
Borin MT; Hughes GS; Spillers CR; Patel RK
Antimicrob Agents Chemother; 1990 Jun; 34(6):1094-9. PubMed ID: 2393268
[TBL] [Abstract][Full Text] [Related]
26. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
Frampton JE; Brogden RN; Langtry HD; Buckley MM
Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
[TBL] [Abstract][Full Text] [Related]
27. Cicloral versus neoral: a bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral.
Kees F; Mair G; Dittmar M; Bucher M
Transplant Proc; 2004 Dec; 36(10):3234-8. PubMed ID: 15686736
[TBL] [Abstract][Full Text] [Related]
28. [The biological availability of cefadroxil given simultaneously with N-acetylcysteine].
Barkworth MF; Mangold B; Rehm KD; Schmieder G; Töberich H; Vinchenzo A; Weber J; Rübartsch C
Arzneimittelforschung; 1991 Aug; 41(8):839-43. PubMed ID: 1781807
[TBL] [Abstract][Full Text] [Related]
29. Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections.
Safran C
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():93-101. PubMed ID: 2292535
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic study and clinical evaluation of cefpodoxime proxetil in the elderly with impaired renal function.
Ishioka T
J Chemother; 1995 Nov; 7 Suppl 4():122-3. PubMed ID: 8904130
[No Abstract] [Full Text] [Related]
31. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.
Stevens DL; Pien F; Drehobl M
Diagn Microbiol Infect Dis; 1993 Feb; 16(2):123-9. PubMed ID: 8467623
[TBL] [Abstract][Full Text] [Related]
32. Clinical trials of cefpodoxime proxetil suspension in paediatrics.
Fujii R
Drugs; 1991; 42 Suppl 3():57-60. PubMed ID: 1726209
[TBL] [Abstract][Full Text] [Related]
33. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.
St Peter JV; Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
Antimicrob Agents Chemother; 1992 Jan; 36(1):126-31. PubMed ID: 1590677
[TBL] [Abstract][Full Text] [Related]
34. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
[TBL] [Abstract][Full Text] [Related]
35. Comparative bioavailability study on naproxen betainate sodium salt monohydrate and naproxen sodium salt in healthy volunteers.
Marzo A; Monti N; Ripamonti M; Marzo P; Wool C; Cerutti R; Maggi GC
Arzneimittelforschung; 1997 Apr; 47(4):385-9. PubMed ID: 9150858
[TBL] [Abstract][Full Text] [Related]
36. Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation.
Scheiwe MW; Lankhaar G; Kleinbloesem CH
Arzneimittelforschung; 1996 Oct; 46(10):960-3. PubMed ID: 8931888
[TBL] [Abstract][Full Text] [Related]
37. Highly sensitive and selective high-performance liquid chromatography method for bioequivalence study of cefpodoxime proxetil in rabbit plasma via fluorescence labeling of its active metabolite.
Ahmed S; Abdel-Wadood HM; Mohamed NA
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Sep; 934():34-40. PubMed ID: 23896427
[TBL] [Abstract][Full Text] [Related]
38. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections.
Cox CE; Graveline JF; Luongo JM
Drugs; 1991; 42 Suppl 3():41-50. PubMed ID: 1726207
[TBL] [Abstract][Full Text] [Related]
39. Disposition of cefpodoxime proxetil in hemodialysis patients.
Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
J Clin Pharmacol; 1992 Nov; 32(11):1038-44. PubMed ID: 1474165
[TBL] [Abstract][Full Text] [Related]
40. A randomized, open-label, crossover study evaluating bioequivalence of two N-acetylcysteine 2% oral solution formulations in healthy subjects
.
Donath F; Armogida M; Shneyer L
Int J Clin Pharmacol Ther; 2018 Sep; 56(9):417-425. PubMed ID: 29956648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
